, RvD1 and PD1 reduced MS-derived monocyte activation and cytokine production, and inhibited inflammation-induced blood-brain barrier dysfunction and monocyte transendothelial migration. Altogether, these findings reveal peripheral defects in the resolution pathway in MS, suggesting pro-resolving LM as novel diagnostic biomarkers and potentially safe therapeutics.
No takes yet. Share an insight, caveat, or question.
Kooij et al. (2019) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: